SG11201806583XA - Compositions containing tucaresol or its analogs - Google Patents
Compositions containing tucaresol or its analogsInfo
- Publication number
- SG11201806583XA SG11201806583XA SG11201806583XA SG11201806583XA SG11201806583XA SG 11201806583X A SG11201806583X A SG 11201806583XA SG 11201806583X A SG11201806583X A SG 11201806583XA SG 11201806583X A SG11201806583X A SG 11201806583XA SG 11201806583X A SG11201806583X A SG 11201806583XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- floor
- compound
- new york
- formula
- Prior art date
Links
- XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229950009795 tucaresol Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 230000006044 T cell activation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 abstract 1
- 229950011498 plinabulin Drugs 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111001110101111011011111101111011111 International Bureau ... .... ..Yjd ..... ...,/ (10) International Publication Number (43) International Publication Date WO 2017/139231 Al 17 August 2017 (17.08.2017) WIPO I PCT (51) International Patent Classification: A61K 31/277 (2006.01) A61K 31/24 (2006.01) A61K 31/235 (2006.01) A61K 31/216 (2006.01) A61K 31/20 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/292,763 8 February 2016 (71) Applicant: BEYONDSPRING INC. [US/US]; 28 Liberty Street, 39th Floor, New York, NY 10005 (US). (72) Inventors: HUANG, Lan; 28 (81) Designated States (unless otherwise indicated, for every A61K 31/192 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/41 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/506 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 39/395 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61P 35/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, PCT/US2017/016740 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 6 February 2017 (06.02.2017) TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. English (84) Designated States (unless otherwise indicated, for every English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (08.02.2016) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, PHARMACEUTICALS, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Liberty Street, 39th Floor, GW, KM, ML, MR, NE, SN, TD, TG). MOHANLAL, Ramon; 28 Published: New York, NY 10005 (US). — with international search report (Art. 21(3)) 28 Liberty Street, 39th Floor, Knobbe, Martens, Olson & 14th Floor, Irvine, CA — New York, NY 10005 (US). _ Liberty Street 39th Floor, LLOYD, George, Kenneth; = New York, NY 10005 (US). — (74) Agent: ARNO, Thomas, R.; = Bear, LLP, 2040 Main Street, 92614 (US). = = = = TUCARESOL OR ITS ANALOGS --0----- PD-1 Ab (54) Title: COMPOSITIONS CONTAINING = 1600— . --4-- PD-1 Ab +13P1 (Tucaresol) = --------- PD-1 Ab + CTLA4 Abs PDAb + CTLA4Ab + BPI ---A--• -1 = *p<0.05 vs. PD-1 Ab alone *pp, 0.01 vs. PD-1 Ab alone = 1000 — = o 1-1 11 0 M 0 ei tz. M ,-, IN Il (57) : Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate 0 to methods of treating cancer by co N ject in need thereof. Some embodiments C plinabulin to a subject in need thereof. cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor. 1 i 1 6 10 16 20 26 Days 76: -administering a compound of formula (I) and one or more immune checkpoint inhibitor to a sub - relate to methods of treating cancer by co-administering a compound of formula (I) and Some embodiments relate to methods of providing co-stimulation of T-cell activation against
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292763P | 2016-02-08 | 2016-02-08 | |
| PCT/US2017/016740 WO2017139231A1 (en) | 2016-02-08 | 2017-02-06 | Compositions containing tucaresol or its analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806583XA true SG11201806583XA (en) | 2018-09-27 |
Family
ID=59563990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806583XA SG11201806583XA (en) | 2016-02-08 | 2017-02-06 | Compositions containing tucaresol or its analogs |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10912748B2 (en) |
| EP (1) | EP3413885A4 (en) |
| JP (2) | JP2019511565A (en) |
| KR (1) | KR20180105685A (en) |
| CN (1) | CN108778267A (en) |
| AU (1) | AU2017217426B2 (en) |
| BR (1) | BR112018016054A2 (en) |
| CA (1) | CA3013467A1 (en) |
| CO (1) | CO2018009096A2 (en) |
| EC (1) | ECSP18067631A (en) |
| IL (1) | IL260933B2 (en) |
| MX (1) | MX2018009413A (en) |
| MY (1) | MY192703A (en) |
| NZ (1) | NZ744854A (en) |
| PH (1) | PH12018501669A1 (en) |
| RU (1) | RU2753543C1 (en) |
| SG (1) | SG11201806583XA (en) |
| WO (1) | WO2017139231A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102623404B1 (en) | 2015-03-06 | 2024-01-11 | 비욘드스프링 파마수티컬스, 인코포레이티드. | How to Treat Brain Tumors |
| EP3265090A4 (en) | 2015-03-06 | 2018-08-01 | Beyondspring Pharmaceuticals Inc. | Method of treating cancer associated with a ras mutation |
| PE20180528A1 (en) | 2015-07-13 | 2018-03-19 | Beyondspring Pharmaceuticals Inc | PLINABULIN COMPOSITIONS |
| MX2018009413A (en) * | 2016-02-08 | 2019-05-15 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs. |
| TWI808055B (en) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-1 inhibitors |
| TWI794171B (en) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Combination therapies of hdac inhibitors and pd-l1 inhibitors |
| KR20240091084A (en) | 2016-06-06 | 2024-06-21 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Composition and method for reducing neutropenia |
| EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
| KR102659907B1 (en) * | 2017-03-13 | 2024-04-24 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Plinabulin composition and uses thereof |
| CN109420167B (en) * | 2017-08-28 | 2022-02-11 | 四川九章生物科技有限公司 | Combined medicine for treating tumor |
| CA3089226A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| BR112021018186A2 (en) * | 2019-03-14 | 2021-11-30 | Engene Inc | Chitosan polyplex-based localized expression of IL-12 alone or in combination with ifn type-I inducers for treatment of mucosal cancers |
| MX2022002607A (en) * | 2019-09-03 | 2022-03-25 | Intra Cellular Therapies Inc | Methods of treatment. |
| CN112778155B (en) * | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | Tucarbaryl derivatives and uses thereof |
| MX2022013808A (en) * | 2020-05-04 | 2023-02-09 | Beyondspring Pharmaceuticals Inc | Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity. |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2053218B (en) * | 1979-06-29 | 1984-01-25 | Wellcome Found | Pharmaceutical ethers of 2,6-dihydroxybenzaldehyde |
| GB2090830B (en) | 1980-12-18 | 1984-09-26 | Wellcome Found | Formyl ether derivatives |
| AU576322B2 (en) | 1983-07-22 | 1988-08-25 | Ici Australia Limited | Alpha-substituted-alpha-cyanomethyl alcohols |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| JPH05255106A (en) | 1990-10-31 | 1993-10-05 | Toray Ind Inc | Medicine for thrombocytopenia |
| JPH059164A (en) | 1991-07-02 | 1993-01-19 | Sumitomo Chem Co Ltd | Production of optically active mandelonitrile derivative |
| GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
| SG48993A1 (en) * | 1992-10-01 | 1998-05-18 | Wellcome Found | Immunopotentiatory agent and physiologically acceptable salts thereof |
| US6096786A (en) * | 1992-10-01 | 2000-08-01 | Glaxo Wellcome Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
| US5872151A (en) * | 1992-10-01 | 1999-02-16 | Glaxo Wellcome Inc. | Immunopotentiatory agents and physiologically acceptable salts thereof |
| ATE169216T1 (en) | 1992-11-27 | 1998-08-15 | Napro Biotherapeutics Inc | INJECTABLE COMPOSITION CONTAINING PACLITAXEL |
| JPH0725858A (en) | 1993-07-13 | 1995-01-27 | Otsuka Pharmaceut Co Ltd | Piperazine derivative |
| US5958980A (en) | 1993-08-26 | 1999-09-28 | Glaxo Wellcome, Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
| IL110787A0 (en) | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
| GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9402809D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9426224D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| US5891877A (en) | 1995-02-14 | 1999-04-06 | Xenova Limited | Pharmaceutical compounds |
| US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| JP3131574B2 (en) | 1996-09-04 | 2001-02-05 | 新日本製鐵株式会社 | Novel antitumor substance, microorganism and method for producing the substance, and cell cycle inhibitor and antitumor agent containing the substance as active ingredient |
| US5939098A (en) | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
| IL136044A (en) | 1997-11-21 | 2005-08-31 | Euro Celtique Sa | 2-aminoacetamide derivatives and pharmaceutical compositions containing the same |
| ATE419233T1 (en) | 1998-01-29 | 2009-01-15 | Aventis Pharma Inc | METHOD FOR PRODUCING AN N-(ALIPHATIC OR AROMATIC) CARBONYL -2-AMINOACETAMIDE COMPOUND AND A CYCLIC COMPOUND |
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US6069146A (en) | 1998-03-25 | 2000-05-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
| ID26031A (en) | 1998-03-26 | 2000-11-16 | Shionogi & Co | INDOL DAMAGES THAT HAVE AN ANTIVIRAL ACTIVITY |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| GB9818627D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
| FR2784988B1 (en) | 1998-10-23 | 2002-09-20 | Adir | NOVEL DIHYDRO AND TETRAHYDROQUINOLEINIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| US6358957B1 (en) | 1998-11-12 | 2002-03-19 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| US7026322B2 (en) | 1998-11-12 | 2006-04-11 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| DK1210428T3 (en) | 1999-08-23 | 2015-06-15 | Dana Farber Cancer Inst Inc | PD-1, a receptor for B7-4 AND USE THEREOF |
| ATE353365T1 (en) | 1999-08-23 | 2007-02-15 | Dana Farber Cancer Inst Inc | NEW B7-4 MOLECULES AND THEIR USES |
| CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| IL150430A0 (en) | 2000-01-18 | 2002-12-01 | Nereus Pharmaceuticals Inc | Cell division inhibitors and process for producing the same |
| JP2003528068A (en) * | 2000-03-17 | 2003-09-24 | コリクサ コーポレイション | New amphiphilic aldehydes and their use as adjuvants and immune effectors |
| ATE417614T1 (en) | 2000-05-09 | 2009-01-15 | Angiorx Corp | PIPERAZINDIONE COMPOUNDS |
| WO2002064592A1 (en) | 2000-12-28 | 2002-08-22 | Neurocrine Biosciences, Inc. | Tricyclic crf receptor antagonists |
| US20030082140A1 (en) | 2001-08-20 | 2003-05-01 | Fisher Paul B. | Combinatorial methods for inducing cancer cell death |
| AU2003213673A1 (en) | 2002-03-01 | 2003-09-16 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| KR20050000544A (en) | 2002-05-17 | 2005-01-05 | 아방티 파르마 소시에테 아노님 | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| AU2003302721B2 (en) | 2002-08-02 | 2009-10-08 | Beyondspring Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| US7935704B2 (en) | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| SE0202429D0 (en) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
| EP1576014B1 (en) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Antibodies against pd-1 and uses thereof |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| KR101228104B1 (en) | 2004-02-04 | 2013-02-01 | 니리어스 파마슈티컬즈, 인코퍼레이션 | Dehydrophenylahistins and Analogs Thereof and the Synthesis of Dehydrophenylahistins and Analogs Thereof |
| HUE029459T2 (en) | 2004-04-19 | 2017-02-28 | Krka Tovarna Zdravil D D Novo Mesto | Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i |
| CA3151350A1 (en) | 2005-05-09 | 2006-11-16 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EA019344B1 (en) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof |
| EP1926724A1 (en) | 2005-09-21 | 2008-06-04 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| JP2009523813A (en) | 2006-01-18 | 2009-06-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Specific therapies using integrin ligands to treat cancer |
| WO2007113648A2 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| ES2527412T3 (en) * | 2007-02-15 | 2015-01-23 | Mannkind Corporation | Method to increase the response of T lymphocytes |
| WO2008128169A1 (en) | 2007-04-13 | 2008-10-23 | Abraxis Bioscience, Inc. | Sparc and methods of use thereof |
| US20090170837A1 (en) | 2007-08-17 | 2009-07-02 | Thallion Pharmaceuticals Inc. | Methods for treating ras driven cancer in a subject |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| WO2009089260A2 (en) | 2008-01-08 | 2009-07-16 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| TWI461423B (en) | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases |
| DK4209510T5 (en) | 2008-12-09 | 2024-07-22 | Hoffmann La Roche | ANTI-PD-L1 ANTIBODIES AND THEIR USE IN PROMOTING T CELL FUNCTION |
| CN102395379B (en) | 2009-01-16 | 2015-07-22 | 特瓦制药工业有限公司 | New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor |
| WO2010114922A1 (en) | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| HUE026005T2 (en) | 2009-08-10 | 2016-04-28 | Univ Texas | Treatment of brain metastases with inhibitors of endothelin receptors in combination with a cytotoxic chemotherapy agent |
| AU2010295646B2 (en) | 2009-09-15 | 2016-02-11 | Ellipses Pharma Limited | Treatment of cancer |
| CA2778707A1 (en) * | 2009-10-23 | 2011-04-28 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| BR112012012465B1 (en) | 2009-11-24 | 2023-03-14 | Medimmune Limited | ISOLATED ANTIBODY OR BINDING FRAGMENT THEREOF WHICH SPECIFICALLY BINDS HUMAN B7-H1, COMPOSITION COMPRISING THE SAME AND USES |
| CN101766815B (en) | 2009-12-31 | 2012-04-25 | 胡松华 | Application of paclitaxel and docetaxel |
| EP2542699A4 (en) | 2010-03-03 | 2013-10-02 | Targeted Molecular Diagnostics Llc | Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification |
| US20130064831A1 (en) | 2010-05-17 | 2013-03-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| US20130131018A1 (en) | 2010-06-04 | 2013-05-23 | Exonhit S.A. | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| JP2012033526A (en) | 2010-07-28 | 2012-02-16 | Fuji Electric Co Ltd | Thin film solar cell and method for manufacturing the same |
| WO2012035436A1 (en) * | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| US20120214679A1 (en) | 2010-11-29 | 2012-08-23 | Precision Therapeutics, Inc. | Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents |
| TWI386203B (en) | 2011-01-07 | 2013-02-21 | Univ China Medical | Pharmaceutical composition for treating brain cancer or reducing temozolomide-resistance of brain cancer cells and uses of the same |
| WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| WO2013078537A1 (en) | 2011-11-28 | 2013-06-06 | National Research Council Of Canada | Paclitaxel response markers for cancer |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| AU2013260101B2 (en) | 2012-05-09 | 2016-10-27 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
| AU2013204313C1 (en) | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
| WO2014066834A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| HUE046961T2 (en) | 2013-02-20 | 2020-04-28 | Univ Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| AU2014244083B2 (en) | 2013-03-13 | 2018-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| JP6526627B2 (en) | 2013-04-24 | 2019-06-05 | テル ハショメール メディカル リサーチ インフラストラクチャー アンド サービシズ リミテッド | Magnetic resonance map for tissue analysis |
| KR20160013049A (en) | 2013-06-03 | 2016-02-03 | 노파르티스 아게 | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| DK3076972T3 (en) | 2013-10-11 | 2022-01-03 | Beyondspring Inc | CANCER TREATMENT WITH COMBINATION OF PLINABULIN AND TAXAN |
| EP4461372A2 (en) * | 2013-11-05 | 2024-11-13 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| AU2014346788B8 (en) | 2013-11-06 | 2021-01-28 | Arizona Board Of Regents On Behalf Of The Unviersity Of Arizona | Method for subtyping lymphoma types by means of expression profiling |
| CN104796448B (en) | 2014-01-22 | 2019-02-12 | 腾讯科技（深圳）有限公司 | The data processing method and device of network system |
| US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| EP3177321B1 (en) * | 2014-08-08 | 2020-11-25 | Oncoquest Pharmaceuticals Inc. | Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancer |
| WO2016081281A1 (en) | 2014-11-17 | 2016-05-26 | Salk Institute For Biological Studies | Lipophilic bisphosphonates and methods of use |
| IL286282B2 (en) | 2015-02-12 | 2023-10-01 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| EP3265090A4 (en) | 2015-03-06 | 2018-08-01 | Beyondspring Pharmaceuticals Inc. | Method of treating cancer associated with a ras mutation |
| KR102623404B1 (en) | 2015-03-06 | 2024-01-11 | 비욘드스프링 파마수티컬스, 인코포레이티드. | How to Treat Brain Tumors |
| WO2016165007A1 (en) | 2015-04-17 | 2016-10-20 | The University Of British Columbia | Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer |
| CN106279039B (en) | 2015-06-02 | 2019-01-11 | 青岛海洋生物医药研究院股份有限公司 | Deuterated dehydrophenylahistin class compound and preparation method thereof and preparing the application in anti-tumor drug |
| PE20180528A1 (en) | 2015-07-13 | 2018-03-19 | Beyondspring Pharmaceuticals Inc | PLINABULIN COMPOSITIONS |
| EP3359692A4 (en) | 2015-10-05 | 2019-05-01 | Cedars-Sinai Medical Center | Method of classifying and diagnosing cancer |
| MX2018009413A (en) * | 2016-02-08 | 2019-05-15 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs. |
| KR20240091084A (en) | 2016-06-06 | 2024-06-21 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Composition and method for reducing neutropenia |
| EP3565812B1 (en) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
| KR102659907B1 (en) | 2017-03-13 | 2024-04-24 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Plinabulin composition and uses thereof |
| WO2019126739A1 (en) | 2017-12-21 | 2019-06-27 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate anti-cancer therapies |
| CA3089226A1 (en) | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
| CN112105363A (en) | 2018-02-01 | 2020-12-18 | 大连万春布林医药有限公司 | Compositions and methods for reducing chemotherapy-induced neutropenia by administering plinabulin and a G-CSF agent |
| CN110240592A (en) | 2018-03-08 | 2019-09-17 | 青岛海洋生物医药研究院股份有限公司 | (Z) -3- (3- formoxyl benzylidene) piperazinedione compounds and its application in preparation of anti-tumor drugs |
| EP3773592A4 (en) | 2018-04-05 | 2022-02-23 | Noviga Research AB | Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer |
| CN112543636B (en) | 2018-06-01 | 2024-03-01 | 大连万春布林医药有限公司 | Compositions and methods for treating cancers associated with EGFR mutations |
| JP2021534183A (en) | 2018-08-16 | 2021-12-09 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Methods and compositions for stimulating an immune response |
| AU2019378779A1 (en) | 2018-11-14 | 2021-06-03 | Beyondspring Pharmaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
| CN112778155B (en) | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | Tucarbaryl derivatives and uses thereof |
| MX2022013808A (en) | 2020-05-04 | 2023-02-09 | Beyondspring Pharmaceuticals Inc | Triple combination therapy for enhancing cancer cell killing in cancers with low immunogenicity. |
-
2017
- 2017-02-06 MX MX2018009413A patent/MX2018009413A/en unknown
- 2017-02-06 BR BR112018016054-7A patent/BR112018016054A2/en not_active Application Discontinuation
- 2017-02-06 CN CN201780018762.6A patent/CN108778267A/en active Pending
- 2017-02-06 EP EP17750611.0A patent/EP3413885A4/en active Pending
- 2017-02-06 NZ NZ744854A patent/NZ744854A/en unknown
- 2017-02-06 RU RU2018128290A patent/RU2753543C1/en active
- 2017-02-06 WO PCT/US2017/016740 patent/WO2017139231A1/en active Application Filing
- 2017-02-06 US US16/075,942 patent/US10912748B2/en active Active
- 2017-02-06 AU AU2017217426A patent/AU2017217426B2/en active Active
- 2017-02-06 IL IL260933A patent/IL260933B2/en unknown
- 2017-02-06 MY MYPI2018702720A patent/MY192703A/en unknown
- 2017-02-06 JP JP2018560724A patent/JP2019511565A/en active Pending
- 2017-02-06 CA CA3013467A patent/CA3013467A1/en active Pending
- 2017-02-06 SG SG11201806583XA patent/SG11201806583XA/en unknown
- 2017-02-06 KR KR1020187024294A patent/KR20180105685A/en not_active Application Discontinuation
-
2018
- 2018-08-06 PH PH12018501669A patent/PH12018501669A1/en unknown
- 2018-08-29 CO CONC2018/0009096A patent/CO2018009096A2/en unknown
- 2018-09-07 EC ECSENADI201867631A patent/ECSP18067631A/en unknown
-
2021
- 2021-02-08 US US17/170,058 patent/US11857522B2/en active Active
-
2022
- 2022-04-07 JP JP2022063979A patent/JP2022088662A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017217426B2 (en) | 2022-12-01 |
| KR20180105685A (en) | 2018-09-28 |
| IL260933B2 (en) | 2023-04-01 |
| CN108778267A (en) | 2018-11-09 |
| MX2018009413A (en) | 2019-05-15 |
| ECSP18067631A (en) | 2018-09-30 |
| JP2022088662A (en) | 2022-06-14 |
| NZ744854A (en) | 2020-01-31 |
| WO2017139231A1 (en) | 2017-08-17 |
| US11857522B2 (en) | 2024-01-02 |
| IL260933A (en) | 2018-10-31 |
| JP2019511565A (en) | 2019-04-25 |
| CO2018009096A2 (en) | 2019-04-30 |
| PH12018501669A1 (en) | 2019-06-17 |
| EP3413885A1 (en) | 2018-12-19 |
| CA3013467A1 (en) | 2017-08-17 |
| RU2753543C1 (en) | 2021-08-17 |
| US20210161844A1 (en) | 2021-06-03 |
| US10912748B2 (en) | 2021-02-09 |
| IL260933B (en) | 2022-12-01 |
| AU2017217426A1 (en) | 2018-08-23 |
| EP3413885A4 (en) | 2019-09-18 |
| BR112018016054A2 (en) | 2019-02-12 |
| MY192703A (en) | 2022-09-02 |
| US20190380983A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201811074RA (en) | Nant cancer vaccine | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases |